Different time schedules affect conditioned place preference after morphine and morphine-6-glucuronide administration

Pharmacology Biochemistry and Behavior

Volumn 89, Issue 3, 2008, Pages 374-383

  Vindenes, Vigdis ^a   Handal, Marte ^a   Ripel, Åse ^a   Thaulow, Cecilie H ^a   Vindenes, Harald B ^c   Boix, Fernando ^a   Mørland, Jørg ^a,b  

^a NORWEGIAN INSTITUTE OF PUBLIC HEALTH   (Norway)

^b UNIVERSITY OF OSLO   (Norway)

^c OSLO UNIVERSITY HOSPITAL   (Norway)

Author keywords

Biphasic locomotor activity; Conditioning; CPP; M6G; Morphine; Morphine 6 glucuronide; Pharmacokinetic; Reward

Indexed keywords

MORPHINE; MORPHINE 6 GLUCURONIDE;

ANIMAL EXPERIMENT; ARTICLE; C57BL 6 MOUSE; CONDITIONED REFLEX; CONTROLLED STUDY; DRUG EFFECT; LOCOMOTION; MALE; MOUSE; NONHUMAN; PLACE PREFERENCE; PRIORITY JOURNAL; TIME PERCEPTION;

ANIMALS; CONDITIONING (PSYCHOLOGY); MALE; MICE; MICE, INBRED C57BL; MORPHINE; MORPHINE DERIVATIVES; MOTOR ACTIVITY; REWARD; TIME FACTORS;

ANIMALIA; MUS;

EID: 40849137677     PISSN: 00913057     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pbb.2008.01.012     Document Type: Article

References (34)

1. Aasmundstad T.A., Morland J., and Paulsen R.E. Distribution of morphine 6-glucuronide and morphine across the blood-brain barrier in awake, freely moving rats investigated by in vivo microdialysis sampling. J Pharmacol Exp Ther 275 (1995) 435-441
2. Abbott F.V., and Franklin K.B. Morphine-6-glucuronide contributes to rewarding effects of opiates. Life Sci 48 (1991) 1157-1163
3. Babbini M., and Davis W.M. Time-dose relationships for locomotor activity effects of morphine after acute or repeated treatment. Br J Pharmacol 46 (1972) 213-224
4. Bardo M.T., Rowlett J.K., and Harris M.J. Conditioned place preference using opiate and stimulant drugs: a meta-analysis. Neurosci Biobehav Rev 19 (1995) 39-51
5. Barjavel M., Sandouk P., Plotkine M., and Scherrmann J.M. Morphine and morphine metabolite kinetics in the rat brain as assessed by transcortical microdialysis. Life Sci 55 (1994) 1301-1308
6. Baumeister A.A., Hurry M., Curtis W., Chaney T.M., Wolf E., and Leoni R.R. The antinociceptive and motivational effects of intranigral injection of opioid agonists. Neuropharmacology 32 (1993) 1299-1303
7. Bickel U., Schumacher O.P., Kang Y.S., and Voigt K. Poor permeability of morphine 3-glucuronide and morphine 6-glucuronide through the blood-brain barrier in the rat. J Pharmacol Exp Ther 278 (1996) 107-113
8. Cadoni C., and Di Chiara G. Differential changes in accumbens shell and core dopamine in behavioral sensitization to nicotine. Eur J Pharmacol 387 (2000) R23-R25
9. Carrupt P.A., Testa B., Bechalany A., el Tayar N., Descas P., and Perrissoud D. Morphine 6-glucuronide and morphine 3-glucuronide as molecular chameleons with unexpected lipophilicity. J Med Chem 34 (1991) 1272-1275
10. Christrup L.L. Morphine metabolites. Acta Anaesthesiol Scand 41 (1997) 116-122
11. Gong Q.L., Hedner J., Bjorkman R., and Hedner T. Morphine-3-glucuronide may functionally antagonize morphine-6-glucuronide induced antinociception and ventilatory depression in the rat. Pain 48 (1992) 249-255
12. Handal M., Grung M., Skurtveit S., Ripel A., and Morland J. Pharmacokinetic differences of morphine and morphine-glucuronides are reflected in locomotor activity. Pharmacol Biochem Behav 73 (2002) 883-892
13. Handal M., Ripel A., Aasmundstad T., Skurtveit S., and Morland J. Morphine-3-glucuronide inhibits morphine induced, but enhances morphine-6-glucuronide induced locomotor activity in mice. Pharmacol Biochem Behav 86 (2007) 576-586
14. Husbands S.M., and Lewis J.W. Opioid ligands having delayed long-term antagonist activity: potential pharmacotherapies for opioid abuse. Mini Rev Med Chem 3 (2003) 137-144
15. Kilpatrick G.J., and Smith T.W. Morphine-6-glucuronide: actions and mechanisms. Med Res Rev 25 (2005) 521-544
16. Lipkowski A.W., Carr D.B., Langlade A., Osgood P.F., and Szyfelbein S.K. Morphine-3-glucuronide: silent regulator of morphine actions. Life Sci 55 (1994) 149-154
17. Lotsch J. Opioid metabolites. J Pain Symptom Manage 29 (2005) S10-S24
18. Morland J., Jones B.L., Palomares M.L., and Alkana R.L. Morphine-6-glucuronide: a potent stimulator of locomotor activity in mice. Life Sci 55 (1994) L163-L168
19. Okura T., Saito M., Nakanishi M., Komiyama N., Fujii A., Yamada S., et al. Different distribution of morphine and morphine-6 beta-glucuronide after intracerebroventricular injection in rats. Br J Pharmacol 140 (2003) 211-217
20. Orsini C., Bonito-Oliva A., Conversi D., and Cabib S. Susceptibility to conditioned place preference induced by addictive drugs in mice of the C57BL/6 and DBA/2 inbred strains. Psychopharmacology (Berl.) 181 (2005) 327-336
21. Parkinson J.A., Olmstead M.C., Burns L.H., Robbins T.W., and Everitt B.J. Dissociation in effects of lesions of the nucleus accumbens core and shell on appetitive pavlovian approach behavior and the potentiation of conditioned reinforcement and locomotor activity by d-amphetamine. J Neurosci 19 (1999) 2401-2411
22. Rook E.J., Huitema A.D., van den B.W., van Ree J.M., and Beijnen J.H. Population pharmacokinetics of heroin and its major metabolites. Clin Pharmacokinet 45 (2006) 401-417
23. Sakoori K., and Murphy N.P. Maintenance of conditioned place preferences and aversion in C57BL6 mice: effects of repeated and drug state testing. Behav Brain Res 160 (2005) 34-43
24. Schnur P., Bravo F., Trujillo M., and Rocha S. Biphasic effects of morphine on locomotor activity in hamsters. Pharmacol Biochem Behav 18 (1983) 357-361
25. Smith M.T. Neuroexcitatory effects of morphine and hydromorphone: evidence implicating the 3-glucuronide metabolites. Clin Exp Pharmacol Physiol 27 (2000) 524-528
26. Stain-Texier F., Boschi G., Sandouk P., and Scherrmann J.M. Elevated concentrations of morphine 6-beta-d-glucuronide in brain extracellular fluid despite low blood-brain barrier permeability. Br J Pharmacol 128 (1999) 917-924
27. Suzuki N., Kalso E., and Rosenberg P.H. Intrathecal morphine-3-glucuronide does not antagonize spinal antinociception by morphine or morphine-6-glucuronide in rats. Eur J Pharmacol 249 (1993) 247-250
28. Tahsili-Fahadan P., Yahyavi-Firouz-Abadi N., Khoshnoodi M.A., Motiei-Langroudi R., Tahaei S.A., Ghahremani M.H., et al. Agmatine potentiates morphine-induced conditioned place preference in mice: modulation by alpha2-adrenoceptors. Neuropsychopharmacology 31 (2006) 1722-1732
29. Timar J., Gyarmati Z., and Furst Z. The development of tolerance to locomotor effects of morphine and the effect of various opioid receptor antagonists in rats chronically treated with morphine. Brain Res Bull 64 (2005) 417-424
30. Tzschentke T.M. Measuring reward with the conditioned place preference paradigm: a comprehensive review of drug effects, recent progress and new issues. Prog Neurobiol 56 (1998) 613-672
31. Vanderschuren L.J., Tjon G.H., Nestby P., Mulder A.H., Schoffelmeer A.N., and De Vries T.J. Morphine-induced long-term sensitization to the locomotor effects of morphine and amphetamine depends on the temporal pattern of the pretreatment regimen. Psychopharmacology (Berl) 131 (1997) 115-122
32. Vindenes V., Handal M., Ripel A., Boix F., and Morland J. Conditioned place preference induced by morphine and morphine-6-glucuronide in mice. Pharmacol Biochem Behav 85 (2006) 292-297
33. Wu D., Kang Y.S., Bickel U., and Pardridge W.M. Blood-brain barrier permeability to morphine-6-glucuronide is markedly reduced compared with morphine. Drug Metab Dispos 25 (1997) 768-771
34. Yoshimura H., Ida S., Oguri K., and Tsukamoto H. Biochemical basis for analgesic activity of morphine-6-glucuronide. I. Penetration of morphine-6-glucuronide in the brain of rats. Biochem Pharmacol 22 (1973) 1423-1430